MNG728
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.548
- INTERFERON_GAMMA_RESPONSE+0.497
- INFLAMMATORY_RESPONSE+0.454
- INTERFERON_ALPHA_RESPONSE+0.442
- IL6_JAK_STAT3_SIGNALING+0.438
- TNFA_SIGNALING_VIA_NFKB+0.429
- ANGIOGENESIS+0.364
- KRAS_SIGNALING_UP+0.353
- IL2_STAT5_SIGNALING+0.327
- COAGULATION+0.292
Top 10 suppressed
- PROTEIN_SECRETION-0.419
- MYC_TARGETS_V1-0.378
- UNFOLDED_PROTEIN_RESPONSE-0.346
- CHOLESTEROL_HOMEOSTASIS-0.319
- DNA_REPAIR-0.319
- MITOTIC_SPINDLE-0.315
- OXIDATIVE_PHOSPHORYLATION-0.313
- MYC_TARGETS_V2-0.284
- PEROXISOME-0.232
- UV_RESPONSE_DN-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1498482 | GTEX | — | 0.914 |
| 2 | MDT-AP-2621 | Med | Medulloblastoma | 0.910 |
| 3 | MNG303 | — | — | 0.902 |
| 4 | SRR1469495 | GTEX | — | 0.897 |
| 5 | MNG943 | — | — | 0.897 |
| 6 | SRR1382532 | GTEX | — | 0.892 |
| 7 | MNG1166 | — | — | 0.888 |
| 8 | SRR597977 | GTEX | — | 0.888 |
| 9 | SRR1071289 | GTEX | — | 0.883 |
| 10 | SRR1389059 | GTEX | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.548 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.497 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.454 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.442 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.438 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.429 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.364 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.353 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.327 | Idelalisib | — uncovered |
| COAGULATION | 0.292 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.272 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.258 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.255 | Idelalisib | — uncovered |
| COMPLEMENT | 0.219 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.202 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.197 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.166 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.152 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.135 | Idelalisib | — uncovered |
| APOPTOSIS | 0.118 | Idelalisib | — uncovered |